RIBOMIC Inc.
4591 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 港区白金台３−１６−１３ 白金台ウスイビル６階
- Website:
- https://www.ribomic.com/eng/
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
RIBOMIC Inc. is a Japanese biotechnology company focused on the development of innovative RNA-targeting therapeutics. Utilizing its proprietary technology platform, RIBOMIC seeks to harness the potential of RNA molecules for drug discovery and development, particularly in the fields of oncology and infectious diseases. The company is dedicated to advancing the understanding of RNA biology to create novel treatment options that address unmet medical needs. RIBOMIC aims to collaborate with global partners, including pharmaceutical companies and research institutions, to accelerate the translation of its research into effective therapies. With a commitment to scientific excellence and innovation, RIBOMIC Inc. is positioned at the forefront of RNA-based therapeutic advancements.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-20 03:50 |
Regulatory News Service
確認書
|
Japanese | 7.9 KB | |
| 2025-06-20 03:49 |
Internal Control over Financial Reporting
内部統制報告書－第22期(2024/04/01－2025/03/31)
|
Japanese | 22.3 KB | |
| 2025-06-20 03:43 |
Annual Report
有価証券報告書－第22期(2024/04/01－2025/03/31)
|
Japanese | 2.0 MB | |
| 2024-11-13 02:14 |
Regulatory News Service
確認書
|
Japanese | 7.9 KB | |
| 2024-11-13 02:13 |
Interim Report
半期報告書－第22期(2024/04/01－2025/03/31)
|
Japanese | 207.6 KB | |
| 2024-06-26 04:47 |
Inside Information Statement
臨時報告書
|
Japanese | 22.7 KB | |
| 2024-06-26 04:45 |
Internal Control over Financial Reporting
内部統制報告書－第21期(2023/04/01－2024/03/31)
|
Japanese | 22.1 KB | |
| 2024-06-26 04:44 |
Regulatory News Service
確認書
|
Japanese | 8.0 KB | |
| 2024-06-26 04:43 |
Annual Report
有価証券報告書－第21期(2023/04/01－2024/03/31)
|
Japanese | 2.0 MB | |
| 2024-02-14 02:26 |
Regulatory News Service
確認書
|
Japanese | 7.9 KB | |
| 2024-02-14 02:25 |
Quarterly Report
四半期報告書－第21期第3四半期(2023/10/01－2023/12/31)
|
Japanese | 178.6 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ABIVAX | France | ABVX | |
|
Addex Therapeutics Ltd | Switzerland | ADXN | |
|
AegirBio AB | Sweden | AEGIR | |
|
AGRONOMICS LIMITED | Isle of Man | ANIC | |
|
AIREA PLC | United Kingdom | AIEA | |
|
Alkaloid AD | North Macedonia | ALK | |
| Alma Yesodot Ltd. | Israel | KVSR | ||
|
Amphastar Pharmaceuticals Inc. | United States of America | AMPH | |
| Ananda Pharma Plc | United Kingdom | N/A | ||
|
AnGes, Inc. | Japan | 4563 |